Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
289.64
+3.16 (1.10%)
At close: Mar 6, 2026, 4:00 PM EST
290.00
+0.36 (0.12%)
After-hours: Mar 6, 2026, 7:59 PM EST
Elevance Health Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Elevance Health stock have an average target of 386.59, with a low estimate of 297 and a high estimate of 485. The average target predicts an increase of 33.47% from the current stock price of 289.64.
Analyst Consensus: Buy
* Price targets were last updated on Feb 2, 2026.
Analyst Ratings
The average analyst rating for Elevance Health stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 6 | 6 | 6 | 7 | 7 |
| Hold | 3 | 6 | 6 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $394 → $397 | Buy | Maintains | $394 → $397 | +37.07% | Feb 2, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $400 → $390 | Strong Buy | Maintains | $400 → $390 | +34.65% | Feb 2, 2026 |
| Barclays | Barclays | Buy Maintains $404 → $393 | Buy | Maintains | $404 → $393 | +35.69% | Jan 30, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $424 → $391 | Buy | Maintains | $424 → $391 | +35.00% | Jan 30, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $414 → $396 | Strong Buy | Maintains | $414 → $396 | +36.72% | Jan 29, 2026 |
Financial Forecast
Revenue This Year
195.93B
from 199.13B
Decreased by -1.61%
Revenue Next Year
202.00B
from 195.93B
Increased by 3.10%
EPS This Year
26.15
from 25.21
Increased by 3.74%
EPS Next Year
29.52
from 26.15
Increased by 12.87%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 218.0B | 229.7B | ||
| Avg | 195.9B | 202.0B | ||
| Low | 183.3B | 190.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 9.5% | 17.2% | ||
| Avg | -1.6% | 3.1% | ||
| Low | -8.0% | -2.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 29.42 | 33.62 | |||
| Avg | 26.15 | 29.52 | |||
| Low | 24.99 | 27.81 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.7% | 28.6% | |||
| Avg | 3.7% | 12.9% | |||
| Low | -0.9% | 6.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.